Cannabis Use in Hospitalized Patients with Chronic Pain

Abstract

Introduction To date, no study has reported the prevalence of cannabis use in chronic pain patients. The aim of this study is to investigate the trends in cannabis use among chronic pain in-patients from 2011 to 2015 in the USA. Methods Patients were identified from the National Inpatient Sample (NIS) database using the International Classification of Diseases, Ninth and Tenth Revision, diagnosis codes for chronic pain and cannabis use. Annual estimates and trends were determined for cannabis use, patient characteristics, cannabis use among subgroups of chronic pain conditions, cost, length of stay, and associated discharge diagnosis. Results Between 2011 to 2015, a total of 247,949 chronic pain patients were cannabis users, increasing from 33,189 to 72,115 ( P < 0.001). There were upward trends of cannabis use in females (38.7–40.7%; P = 0.03), Medicare insured patients (32.7–40.4%; P < 0.01), patients with lowest annual household income (36.1–40.9%; P = 0.02), patients aged 45–64 years (45.9–49.2%; P < 0.001), and patients with tobacco use disorder (63.8–72.4%; P < 0.0001). Concurrently, cannabis use decreased among patients with opioid use disorder (23.8–19.9%; P < 0.001). Cannabis use increased from 2011 to 2015 in patients with chronic regional pain syndrome, trauma, spondylosis, and failed back surgery syndrome. Adjusted total hospitalization cost increased from $31,271 ($1333) in 2011 to $38,684 ($946) in 2015 ( P < 0.001). Conclusions Cannabis use increased substantially from 2011 to 2015, while the rates of cannabis use in opioid users down-trended simultaneously. Disparities in cannabis use among subgroups should be explored further. Electronic supplementary material The online version of this article (10.1007/s12325-020-01416-9) contains supplementary material, which is available to authorized users.

Prevalence of cannabis use for pain management in Quebec: A post-legalization estimate among generations living with chronic pain

“…Baby boomers did not stand out in terms of cannabis use, although cannabis use was more prevalent among this generation in the 1960s and 1970s, which could be a factor influencing openness toward cannabis use. 56 Our results are in line with other studies suggesting that cannabis use is higher in younger age groups and not often use in those aged 75 years and older (both in CP populations 10, 57 and in the general Canadian population 58 ). The age groups with the highest cannabis use were those ≤26 and 27–47 years old, in accordance with previous investigations.…”

Medical Cannabis, Headaches, and Migraines: A Review of the Current Literature

“…Despite the limitations of the above studies, medical cannabis is an effective alternative treatment for managing headache and migraine symptoms. Our review article shows that cannabis use is picking up in patients with chronic pain and can be expected to continue to rise upwards in the face of increasing societal awareness and availability of legal cannabis [ 33 ]. Careful questioning and discussing with the patients about the use of marijuana, its risks, and benefits should be documented and researched.…”

Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition

“…The use of cannabis and cannabis products for therapeutic or medical reasons is increasing due to increased consumer demand, regulatory changes enabling easier access to cannabis products [1] and an emerging evidence base for the effectiveness of cannabis in treating a range of health conditions [2][3][4][5][6]. Some studies suggest that medical cannabis use is not uncommon, with 20-40% of patients with cancer [7][8][9] and 4-16% [10,11] of patients with chronic, non-cancer pain reporting use of cannabis to treat their conditions and/or side-effects of other medication (e.g. chemotherapy-induced nausea and vomiting).…”